VJOncology is committed to improving our service to you

ASCO 2020 | RAMES: ramucirumab + gemcitabine in relapsed mesothelioma patients

VJOncology is committed to improving our service to you

Dean Fennell

Dean Fennell, PhD, FRCP, of the University Hospitals Of Leicester NHS Trust, Leicester, UK discusses the result of the RAMES study (NCT03560973) which was evaluating the addition of ramucirumab, a VEGFR2 inhibitor, to gemcitabine in relapsed mesothelioma patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter